Monthly Prescribing Reference

Updated Sublocade Label Includes Rapid Induction, Alternative Injection Sites

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Seeking Alpha

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) ...
Pharmabiz

AbbVie seeks US FDA approval for Skyrizi subcutaneous induction for adults with moderately to severely active Crohn's disease

AbbVie seeks US FDA approval for Skyrizi subcutaneous induction for adults with moderately to severely active Crohn's disease: North Chicago, Illinois Wednesday, April 29, 2026, 1 ...